MilgoSense

Company Overview

Snapshot

Founded in December 2023 by Dovi Kelman, MilgoSense operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing an AI-based diagnostic tool for schizophrenia.

Business overview

MilgoSense is an early-stage venture developing an AI-based diagnostic tool for schizophrenia. The company aims to provide a simple, non-invasive, cheap, and remote solution to disrupt the diagnosis, monitoring, and decision-making processes for this severe mental disorder. MilgoSense focuses on addressing the unmet need for an objective decision-support tool, particularly for teenagers, to facilitate early diagnosis and treatment. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics, leveraging Artificial Intelligence to serve healthcare providers.

Company Intelligence Q&A

What is MilgoSense's primary focus?

MilgoSense is focused on developing an AI-based diagnostic tool for schizophrenia, aiming to improve diagnosis, monitoring, and decision-making for the condition.

When was MilgoSense founded?

MilgoSense was founded in December 2023.

Who is the founder of MilgoSense?

Dovi Kelman is the Founder & CEO of MilgoSense.

What problem is MilgoSense trying to solve?

MilgoSense aims to address the lack of an objective decision-support tool for schizophrenia diagnosis, particularly for teenagers, to enable earlier intervention and reduce long-term healthcare burdens.

In which sector does MilgoSense primarily operate?

MilgoSense operates primarily in the Health Tech & Life Sciences sector, with a focus on Digital Healthcare and Digital Medical Diagnostics.